Vaginal ring treats vasomotor and local symptoms
Healthcare professionals will soon be able to offer women the first vaginal estrogen product that treats both the vasomotor and vaginal symptoms of menopause. The FDA recently approved estradiol (Femring, Galen Holdings) vaginal ring for the treatment of moderate to severe vasomotor symptoms associated with menopause and treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. Femring will be available in pharmacies in June.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
